These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 1381239

  • 1. Kit ligand improves in vitro erythropoiesis in myelodysplastic syndrome.
    Backx B, Broeders L, Löwenberg B.
    Blood; 1992 Sep 01; 80(5):1213-7. PubMed ID: 1381239
    [Abstract] [Full Text] [Related]

  • 2. Erythropoiesis in myelodysplastic syndrome: expression of receptors for erythropoietin and kit ligand.
    Backx B, Broeders L, Hoefsloot LH, Wognum B, Löwenberg B.
    Leukemia; 1996 Mar 01; 10(3):466-72. PubMed ID: 8642863
    [Abstract] [Full Text] [Related]

  • 3. The effect of stem-cell factor, interleukin-3 and erythropoietin on in vitro erythropoiesis in myelodysplastic syndromes.
    Verbeek W, Vehmeyer K, Wörmann B, Hiddemann W.
    J Cancer Res Clin Oncol; 1995 Mar 01; 121(6):338-42. PubMed ID: 7797598
    [Abstract] [Full Text] [Related]

  • 4. Growth analysis of marrow CD34-positive hematopoietic progenitor cells in patients with myelodysplastic syndromes.
    Asano H, Hotta T, Ichihara M, Murate T, Kobayashi M, Saito H.
    Leukemia; 1994 May 01; 8(5):833-8. PubMed ID: 7514249
    [Abstract] [Full Text] [Related]

  • 5. In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels.
    Zwierzina H, Bammer T, Rollinger-Holzinger I, Herold M, Fenaux P, Nüssler V, Hoflehner E, Geissler D.
    Clin Cancer Res; 1996 Jun 01; 2(6):1031-8. PubMed ID: 9816264
    [Abstract] [Full Text] [Related]

  • 6. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis.
    Claessens YE, Bouscary D, Dupont JM, Picard F, Melle J, Gisselbrecht S, Lacombe C, Dreyfus F, Mayeux P, Fontenay-Roupie M.
    Blood; 2002 Mar 01; 99(5):1594-601. PubMed ID: 11861273
    [Abstract] [Full Text] [Related]

  • 7. Mast cell growth factor (c-kit ligand) restores growth of multipotent progenitors in myelodysplastic syndrome.
    Glinsmann-Gibson B, Spier C, Baier M, Taetle R, Broudy VC, List AF.
    Leukemia; 1994 May 01; 8(5):827-32. PubMed ID: 7514248
    [Abstract] [Full Text] [Related]

  • 8. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
    Rosati S, Mick R, Xu F, Stonys E, Le Beau MM, Larson R, Vardiman JW.
    Leukemia; 1996 Jan 01; 10(1):20-6. PubMed ID: 8558932
    [Abstract] [Full Text] [Related]

  • 9. CD34+/CD36- cells from myelodysplasia patients have a limited capacity to proliferate but can differentiate in response to Epo and MGF stimulation.
    Brada SJ, de Wolf JT, Hendriks DW, Smit JW, Vellenga E.
    Leukemia; 1998 Jun 01; 12(6):882-6. PubMed ID: 9639415
    [Abstract] [Full Text] [Related]

  • 10. Effect of mast cell growth factor (c-kit ligand) on clonogenic leukemic precursor cells.
    Goselink HM, Williams DE, Fibbe WE, Wessels HW, Beverstock GC, Willemze R, Falkenburg JH.
    Blood; 1992 Aug 01; 80(3):750-7. PubMed ID: 1638026
    [Abstract] [Full Text] [Related]

  • 11. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
    Bouscary D, De Vos J, Guesnu M, Jondeau K, Viguier F, Melle J, Picard F, Dreyfus F, Fontenay-Roupie M.
    Leukemia; 1997 Jun 01; 11(6):839-45. PubMed ID: 9177438
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
    Schmitt-Graeff A, Mattern D, Köhler H, Hezel J, Lübbert M.
    Pathologe; 2000 Jan 01; 21(1):1-15. PubMed ID: 10663664
    [Abstract] [Full Text] [Related]

  • 14. Role of cytokines in leukemic type growth of myelodysplastic CD34+ cells.
    Sawada K, Ieko M, Notoya A, Tarumi T, Koizumi K, Kitayama S, Nishio H, Fukada Y, Yasukouchi T, Yamaguchi M, Katoh S, Koike T.
    Blood; 1996 Jul 01; 88(1):319-27. PubMed ID: 8704190
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Increased peripheral stem cell pool in MDS: an indication of disease progression?
    Vehmeyer K, Haase D, Alves F.
    Leuk Res; 2001 Nov 01; 25(11):955-9. PubMed ID: 11597730
    [Abstract] [Full Text] [Related]

  • 17. Effect of stem cell factor (c-kit ligand) on clonogenic leukemic precursor cells: synergy with other hematopoietic growth factors.
    Wu HK, Chiba S, Hirai H, Takaku F, Yazaki Y.
    Am J Hematol; 1994 Dec 01; 47(4):328-30. PubMed ID: 7526682
    [Abstract] [Full Text] [Related]

  • 18. Characterization of the erythropoiesis in myelodysplasia by means of ferrokinetic studies, in vitro erythroid colony formation and soluble transferrin receptor.
    Brada SJ, de Wolf JT, Hendriks D, Louwes H, van den Berg E, Vellenga E.
    Leukemia; 1998 Mar 01; 12(3):340-5. PubMed ID: 9529128
    [Abstract] [Full Text] [Related]

  • 19. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.
    Wimazal F, Krauth MT, Vales A, Böhm A, Agis H, Sonneck K, Aichberger KJ, Mayerhofer M, Simonitsch-Klupp I, Müllauer L, Sperr WR, Valent P.
    Leuk Lymphoma; 2006 Mar 01; 47(3):451-60. PubMed ID: 16396768
    [Abstract] [Full Text] [Related]

  • 20. Measurement of secondary colony formation after 5 weeks in long-term cultures in patients with myelodysplastic syndrome.
    Sato T, Kim S, Selleri C, Young NS, Maciejewski JP.
    Leukemia; 1998 Aug 01; 12(8):1187-94. PubMed ID: 9697872
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.